Evidence map›Paper›PMID 35973227›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2022

Obesity and Breast Cancer Metastasis across Genomic Subtypes.

Linnea T Olsson, Andrea Walens, Alina M Hamilton, Halei C Benefield, Jodie M Fleming, Lisa A Carey, Stephen D Hursting, Kevin P Williams, Melissa A Troester

Open access · bronzeAbstract read
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Linnea T OlssonDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.ORCID 0000-0002-2786-5966
Andrea WalensLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.ORCID 0000-0001-8706-563X
Alina M HamiltonDepartment of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.ORCID 0000-0001-9121-7114
Halei C BenefieldDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Jodie M FlemingLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.ORCID 0000-0003-0297-5197
Lisa A CareyLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.ORCID 0000-0003-2388-4649
Stephen D HurstingDepartment of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.ORCID 0000-0003-3605-2833
Kevin P Williams *Biomanufacturing Research Institute and Technology Enterprise, North Carolina Central University, Durham, North Carolina.ORCID 0000-0002-6930-4630
Melissa A Troester *Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.ORCID 0000-0001-9506-6624
University of North Carolina at Chapel Hill · USNorth Carolina Central University · US

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
Tissue Procurement & PathologyP50CA058223 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BENJAMIN CARLISLE CALHOUN · 1992 to 2026
$59.3M
Understanding Perceptions of HIV Risk, PrEP, and PrEP use among African American Women Attending an HBCUU54MD012392 · NIMHD · NORTH CAROLINA CENTRAL UNIVERSITY · PI Cherise Baldwin Harrington · 2017 to 2026
$38.1M
UNC-CH CENTER FOR ENVIRONMENTAL HEALTH &SUSCEPTIBILITYP30ES010126 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Hazel B Nichols · 2001 to 2026
$36.3M
Reproduction, Lactation and Hormonal Factors in Breast Cancer SubtypesP01CA151135 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI AMBROSONE, CHRISTINE B., OLSHAN, ANDREW · 2011 to 2017
$18.1M
Targeting the MEKK2-ERK5 Signaling Node in Triple Negative Breast CancerU54CA156735 · NCI · NORTH CAROLINA CENTRAL UNIVERSITY · PI RICHARDSON, MICHELER RICARDO · 2010 to 2021
$13.0M
Targeting the MEKK2-ERK5 Signaling Node in Triple Negative Breast CancerU54CA156733 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SANCAR, GWENDOLYN B · 2010 to 2020
$9.7M
Cancer Control Education ProgramT32CA057726 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Melissa B Gilkey, Melissa A. Troester · 2017 to 2026
$3.7M
NCI NIH HHS P01 CA151135NCI NIH HHS P30 CA016086NCI NIH HHS P50 CA058223NCI NIH HHS T32 CA057726NCI NIH HHS U54 CA156733NCI NIH HHS U54 CA156735NIEHS NIH HHS P30 ES010126NIMHD NIH HHS U54 MD012392
6 · The paper itself

Abstract

backgroundObese women have higher risk of aggressive breast tumors and distant metastasis. However, obesity has rarely been assessed in association with metastasis in diverse populations.

methodsIn the Carolina Breast Cancer Study Phase 3 (2008-2013), waist-to-hip ratio (WHR), body mass index (BMI), and molecular subtype [PAM50 risk-of-recurrence (ROR) score] were assessed. Obesity measures were evaluated in association with metastasis within five years of diagnosis, overall and stratified by race and ROR score. Absolute risk of metastasis and risk differences between strata were calculated using the Kaplan-Meier estimator, adjusted for age, grade, stage, race, and ER status. Relative frequency of metastatic site and multiplicity were estimated in association with obesity using generalized linear models.

resultsHigh-WHR was associated with higher risk of metastasis (5-year risk difference, RD, 4.3%; 95% confidence interval, 2.2-6.5). It was also associated with multiple metastases and metastases at all sites except brain. The 5-year risk of metastasis differed by race (11.2% and 6.9% in Black and non-Black, respectively) and ROR score (19.5% vs. 6.6% in high vs. low-to-intermediate ROR-PT). Non-Black women and those with low-to-intermediate ROR scores had similar risk in high- and low-WHR strata. However, among Black women and those with high ROR, risk of metastasis was elevated among high-WHR (RDBlack/non-Black = 4.6%, RDHigh/Low-Int = 3.1%). Patterns of metastasis were similar by BMI.

conclusionsWHR is associated with metastatic risk, particularly among Black women and those with high-risk tumors. IMPACT: Understanding how risk factors for metastasis interact may help in tailoring care plans and surveillance among patients with breast cancer.

Indexed as

Breast NeoplasmsNeoplasms, Second PrimaryBody Mass IndexClinical Trials, Phase III as TopicFemaleGenomicsHumansObesityPrognosisRisk Factors

Identifiers

PMID35973227
PMCPMC9628732
OpenAlexW4292014166

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.